ICU Medical, Inc. $ICUI Stake Reduced by Pacific Capital Partners Ltd

Key Points

• Pacific Capital Partners Ltd reduced its stake in ICU Medical by 43.2% in the second quarter, now holding approximately 0.21% of the company valued at $6.94 million.
• ICU Medical reported an EPS of $2.10, exceeding forecasts, with quarterly revenue of $543.57 million, although this marked an 8.0% decline year-over-year.
• Recent analyst ratings for ICU Medical range from strong-buy to buy, with a consensus target price of $181.00.

Pacific Capital Partners Ltd decreased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 43.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 52,500 shares of the medical instruments supplier's stock after selling 40,000 shares during the quarter. ICU Medical makes up 6.5% of Pacific Capital Partners Ltd's investment portfolio, making the stock its 3rd largest position. Pacific Capital Partners Ltd owned approximately 0.21% of ICU Medical worth $6,938,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Xponance Inc. grew its stake in shares of ICU Medical by 5.3% during the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock worth $238,000 after acquiring an additional 86 shares during the period. Blue Trust Inc. lifted its holdings in ICU Medical by 23.0% during the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after purchasing an additional 150 shares in the last quarter. GAMMA Investing LLC lifted its holdings in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares in the last quarter. Vise Technologies Inc. grew its stake in ICU Medical by 7.1% during the fourth quarter. Vise Technologies Inc. now owns 2,649 shares of the medical instruments supplier's stock valued at $411,000 after acquiring an additional 176 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock valued at $1,297,000 after acquiring an additional 229 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical Trading Down 1.8%

ICU Medical stock traded down $2.44 during mid-day trading on Friday, reaching $130.59. 110,238 shares of the company traded hands, compared to its average volume of 268,652. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The firm's 50 day moving average price is $126.01 and its 200 day moving average price is $133.39. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -85.53 and a beta of 0.86. ICU Medical, Inc. has a 52-week low of $107.00 and a 52-week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. During the same period in the previous year, the company posted $1.56 earnings per share. The firm's revenue was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other news, Director David C. Greenberg purchased 1,200 shares of the company's stock in a transaction that occurred on Wednesday, August 27th. The shares were bought at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares of the company's stock, valued at $1,006,303.20. This trade represents a 17.75% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Vivek Jain purchased 21,929 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the transaction, the chief executive officer directly owned 130,149 shares of the company's stock, valued at $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ICUI shares. Raymond James Financial reduced their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. Piper Sandler boosted their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Finally, Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, ICU Medical currently has an average rating of "Buy" and an average target price of $181.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.